Biohaven Ltd., a global clinical-stage biopharmaceutical company, has shared promising updates and preliminary clinical data from its oncology development programs. At their 2025 R&D Day, Biohaven highlighted advancements in its portfolio of innovative technologies aimed at modernizing next-generation antibody-drug conjugates (ADCs) through strategic collaborations. Early clinical data for BHV-1510, a Trop2 ADC, indicated potential synergy with anti-PD-1 therapy and promising efficacy for patients who failed standard treatments. This supports the advancement of BHV-1510 into earlier lines of therapy. Furthermore, the initiation of a first-in-human study for BHV-1530, an FGFR3 directed ADC, underscored Biohaven's versatility in generating novel drugs. These developments, combined with collaborations with Merus and GeneQuantum, and licensed technology from Yale University, position Biohaven's platform to potentially deliver a range of differentiated ADC therapies with enhanced potency and selectivity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。